 SEATTLE, WA and VANCOUVER, BC ACCESSWIRE July 22, 2021 Achieve Life Sciences, Inc. NASDAQ:ACHV, a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been awarded a grant from the National Institute on Drug Abuse NIDA of the National Institutes of Health NIH to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. This initial grant award, to commence on August 1, 2021, will be utilized to complete critical regulatory and clinical operational activities, such as protocol finalization, clinical trial site identification, and submission of a new IND to FDA for investigating cytisinicline in nicotine e-cigarette users. 